Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024
Immutep (ASX: IMM; NASDAQ: IMMP) announces a late-breaking abstract for oral presentation at the 2024 ESMO Congress in Barcelona. The presentation will detail results from the randomized TACTI-003 Phase IIb trial evaluating eftilagimod alpha (efti) in combination with pembrolizumab versus pembrolizumab alone in first-line head and neck squamous cell carcinoma patients with any PD-L1 expression (CPS >1).
The presentation, titled 'Primary Results from TACTI-003,' will be delivered by Dr. Claus Andrup Kristensen on September 15, 2024. This selection as a Proffered Paper indicates high-quality research with potential implications for clinical practice or disease understanding.
Immutep (ASX: IMM; NASDAQ: IMMP) annuncia un abstract di ultima ora per una presentazione orale al Congresso ESMO 2024 a Barcellona. La presentazione fornirà dettagli sui risultati del trial randomizzato TACTI-003 Fase IIb che valuta eftilagimod alfa (efti) in combinazione con pembrolizumab rispetto a pembrolizumab da solo nei pazienti con carcinoma squamoso della testa e del collo in prima linea con qualsiasi espressione di PD-L1 (CPS >1).
La presentazione, intitolata 'Risultati Primari da TACTI-003,' sarà effettuata dal Dr. Claus Andrup Kristensen il 15 settembre 2024. Questa selezione come Proffered Paper indica una ricerca di alta qualità con potenziali implicazioni per la pratica clinica o la comprensione della malattia.
Immutep (ASX: IMM; NASDAQ: IMMP) anuncia un abstract de última hora para una presentación oral en el Congreso ESMO 2024 en Barcelona. La presentación detallará los resultados del ensayo aleatorizado TACTI-003 Fase IIb que evalúa eftilagimod alfa (efti) en combinación con pembrolizumab frente a pembrolizumab solo en pacientes con carcinoma de células escamosas de cabeza y cuello en primera línea con cualquier expresión de PD-L1 (CPS >1).
La presentación, titulada 'Resultados Primarios de TACTI-003,' será realizada por el Dr. Claus Andrup Kristensen el 15 de septiembre de 2024. Esta selección como Proffered Paper indica una investigación de alta calidad con posibles implicaciones para la práctica clínica o la comprensión de la enfermedad.
Immutep (ASX: IMM; NASDAQ: IMMP)가 바르셀로나에서 열리는 2024 ESMO Congress에서 구술 발표를 위한 최신 초록을 발표한다고 알렸습니다. 이 발표는 에프틸라지모드 알파 (efti)와 펨브롤리주맙의 조합을 평가한 무작위 TACTI-003 2b 상임상 시험의 결과를 자세히 설명할 것입니다. 이 연구는 PD-L1 발현이 있는 첫 번째 라인 두경부 편평세포 암 환자들을 대상으로 합니다(CPS >1).
'TACTI-003의 주요 결과'라는 제목의 발표는 2024년 9월 15일 드 클라우스 안드룹 크리스텐센이 진행할 것입니다. 프로퍼드 페이퍼로의 선발은 임상 실습이나 질병 이해에 대한 잠재적 영향을 가진 높은 품질의 연구를 의미합니다.
Immutep (ASX: IMM; NASDAQ: IMMP) annonce un abstract de dernière minute pour une présentation orale au Congrès ESMO 2024 à Barcelone. La présentation détaillera les résultats de l'
La présentation, intitulée 'Résultats principaux de TACTI-003,' sera réalisée par le Dr. Claus Andrup Kristensen le 15 septembre 2024. Cette sélection comme Proffered Paper indique une recherche de haute qualité avec des implications potentielles pour la pratique clinique ou la compréhension de la maladie.
Immutep (ASX: IMM; NASDAQ: IMMP) kündigt ein spät eingereichtes Abstract für eine mündliche Präsentation auf dem ESMO Kongress 2024 in Barcelona an. Die Präsentation wird die Ergebnisse der randomisierten TACTI-003 Phase IIb Studie vorstellen, die eftilagimod alpha (efti) in Kombination mit Pembrolizumab im Vergleich zu Pembrolizumab allein bei Patienten mit Plattenepithelkarzinom im Kopf- und Halsbereich in der ersten Linie mit jeglicher PD-L1-Expression (CPS >1) bewertet.
Die Präsentation mit dem Titel 'Primäre Ergebnisse aus TACTI-003' wird am 15. September 2024 von Dr. Claus Andrup Kristensen gehalten. Diese Auswahl als Proffered Paper zeigt eine qualitativ hochwertige Forschung mit potenziellen Auswirkungen auf die klinische Praxis oder das Verständnis der Erkrankung.
- Late-breaking abstract accepted for oral presentation at ESMO Congress 2024
- Presentation will showcase results from randomized Phase IIb trial in head and neck cancer
- Selection as a Proffered Paper indicates high-quality research with potential clinical implications
- None.
Media Release
- Oral presentation will detail results from the randomized TACTI-003 Phase IIb trial in first line head & neck squamous cell carcinoma patients with any PD-L1 expression (CPS >1)
SYDNEY, AUSTRALIA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces a late-breaking abstract has been accepted and selected as a Proffered Paper oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress, taking place September 13-17 in Barcelona, Spain.
The oral presentation will detail results from the randomized Cohort A of the TACTI-003 (KEYNOTE-C34) Phase IIb trial evaluating eftilagimod alpha (“efti”), a proprietary soluble LAG-3 protein and MHC Class II agonist, in combination with pembrolizumab versus pembrolizumab alone in recurrent or metastatic first line head and neck squamous cell carcinoma patients with any PD-L1 expression (CPS >1). Details of the presentation are as follows:
| Title: | Primary Results from TACTI-003: A Randomized Phase IIb Trial Comparing Eftilagimod Alpha (soluble LAG-3) Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with CPS ≥1 |
| Speaker: | Claus Andrup Kristensen, MD, PhD, Head of Section for Thoracic and Head and Neck Oncology, Rigshospitalet, Copenhagen, Denmark |
| Presentation #: | LBA35 |
| Category: | Proffered Paper session: Head and neck cancer |
| Date & Time: | Sunday, September 15, 2024; 10:25 – 10:35 am CET |
Late-breaking abstracts are generally reserved for high-quality, new research findings from randomized phase II or phase III trials with implications for clinical practice or understanding of disease processes. Proffered papers are oral presentations of original data of superior quality, followed by expert discussion and perspectives.
About TACTI-003
The Two ACTive Immunotherapies-003 (TACTI-003) trial is an ongoing Phase IIb study (also known as KEYNOTE-C34) evaluating eftilagimod alpha (efti), Immutep’s proprietary soluble LAG-3 protein and MHC Class II agonist, in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The randomized Cohort A portion of the study is evaluating efti in combination with pembrolizumab as compared to pembrolizumab monotherapy in patients with PD-L1 positive (Combined Positive Score [CPS] ≥1) tumours, whereas Cohort B is evaluating efti in combination with pembrolizumab in patients with PD-L1 negative tumours (CPS <1).
The primary endpoint of the study is Objective Response Rate of evaluable patients according to RECIST 1.1. Secondary endpoints include Overall Survival, Objective Response Rate according to iRECIST, Progression Free Survival, and Duration of Response. For more information about the Phase IIb trial, visit clinicaltrials.gov (NCT04811027).
About Immutep
Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:
Catherine Strong, Sodali & Co.
+61 (0)406 759 268; catherine.strong@sodali.com
U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
FAQ
What is the TACTI-003 trial evaluating for Immutep (IMMP)?
When and where will Immutep (IMMP) present its TACTI-003 trial results?
What is the significance of Immutep's (IMMP) abstract being selected as a late-breaking presentation at ESMO 2024?
Who will be presenting Immutep's (IMMP) TACTI-003 trial results at ESMO 2024?
